Antihepatitis B response to hepatitis B vaccine administered simultaneously with tetanus toxoid in nonresponder individuals

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 243-246

  Sönmez, Emine ^a   Sönmez, Ali Suha ^b   Bayindir, Yaşar ^c   Coskun, Diler ^a   Aritürk, Sedat ^a  

^a KADIR HAS UNIVERSITY   (Turkey)

^b Suleymaniye Maternity and Women s Disease Education and Research Hospital   (Turkey)

^c INONU UNIVERSITY   (Turkey)

Author keywords

Hepatitis B vaccine; Nonresponder; Tetanus toxoid

Indexed keywords

GENHEVAC; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; TE ANATOXEL; TETANUS TOXOID; RECOMBINANT VACCINE; VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; SEROCONVERSION; TETANUS; TREATMENT OUTCOME; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETANUS TOXOID; VACCINATION; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 0037073575     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00452-8     Document Type: Article

References (20)

1. George J., John G.T., Jacop C.K.et al. Active immunization against hepatitis B infection in a haemodialysis population. Nat. Med. J. India. 713:1994;115-116.
2. Del Canho R., Grosheide P.M., Schalm S.W.et al. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J. Hepatol. 20(4):1994;483-486.
3. Strue J., Aranson B., Frening B.et al. Seroconversion after additional vaccine doses to nonresponders three doses of intradermally administered recombinant hepatitis B vaccine. Scand. J. Infect. Dis. 26(4):1994;468-470.
4. Barnaba V., Franco A., Alberti A.et al. Selective killing of hepatitis B envelope antigen-specific B cells by class 1-restricted exogenous antigen-specific T-lymphocytes. Nature. 345:1990;258-260.
5. Desombere I., Hauser P., Rossau R.et al. Nonresponders to hepatitis B vaccine can present envelope particles to T-lymphocytes. Immunology. 154:1995;520-524.
6. Yamashiki M., Kosaka Y., Kondo I., Nomoto M. Impaired cytokine production by peripheral T-lymphocytes in low responders to hepatitis B vaccination. Clin. Sci. 92(5):1997;527-528.
7. Navarro J.F., Teruel J.L., Mateos M.L., Ortuño J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am. J. Nephrol. 16:1996;95-97.
8. Pol S., Legendre C., Mattlinger B., Berthelot P., Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J. Hepatol. 11:1990;385-387.
9. Stachowski J., Kramer J., Fust G., Maciejewski J., Baldamus C.A., Petrani G.G. Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand. J. Immunol. 42:1995;60-65.
10. Zuckerman J.N., Zuckerman A.J., Symington I., Du W., Williams A., Dickson B.et al. Evaluation of new hepatitis B triple antigen vaccine in inadequate responders to current vaccines. Hepatology. 34(4):2001;792-802.
11. Akahane Y. Clinical trial of a preS2 containing recombinant hepatitis B vaccine. In: Nishioka KI, Suzuki H, Mishiora S, Oda T, editors. Viral Hepatitis and Liver Diseases. Tokyo: Springer; 1994. p. 533-5.
12. Smith-Leijs M.B.L., Kramer P., Heijtink R.A.et al. Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasma-derived vaccine with and without preS2 antigen. Eur. J. Clin. Investig. 20:1990;540-545.
13. Tele S.A., Martins R.M., Lopes C.L., dos Santos Carneiro M.A., Souza K.P., Yoshida C.F. Immunogenicity of recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur. J. Epidemiol. 17(2):2001;145-149.
14. Sönmez E., Ozerol H.I., Sahin K., Ozbilge H., Arslan G., Yýlmaz S.et al. Clinical trial of simultaneous administration of preS2 and S containing recombinant hepatitis B vaccine and tetanus toxoid in nonresponder groups: a preliminary study. Turk. J. Med. Res. 15(2):1997;68-71.
15. Hemmerling AE, Muller Firusion N, et al. Clinical experience with preS2 containing hepatitis B vaccine (HG-3) in different nonresponder groups. In: Nishioka K, Suzuki H, Mishiora S, Oda T, editors. Viral Hepatitis and Liver Diseases. Tokyo: Springer; 1994. p. 540-2.
16. Stevens C.E., Alter H.J., Taylor P.W.et al. Hepatitis B vaccine patients receiving haemodialysis. N. Engl. J. Med. 311:1984;469-501.
17. Healy C.M., Cafferkey M.T., Butler K.M.et al. Antenatal hepatitis B screening - is there a need for a national policy? Ir. Med. J. 94(4):2001;111-114.
18. West D.J., Rabalais G.B., Watson B., Keyserling H.L., Matthews H., Hesley T.M. Antibody responses of healthy infants to concurrent administration of bivalent haemophilus influenzae type b- hepatitis B vaccine with diphteria-tetanus-pertussis, polio and measles-mumps-rubella vaccine. BioDrugs. 15(6):2001;413-418.
19. Omeneca F., Dal-Re R., D'Apuzzo V.et al. Reactogenicity of DTPa-HBV/Hib vaccines administered simultaneously at separate sites to infants at 2, 4, and 6 months of age. Vaccine. 19/20(30):2001;4260-4266.
20. Prikazsky V., Boch H.L. Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4, and 5 months of age in Slovakia. Int. J. Clin. Pract. 55(3):2001;156-161.